IMMY18128 / Seattle / Brea Lipe
Research Question:
Is SEA-BCMA tan effective treatment for multiple myeloma (MM) and what side effects
(unwanted effects) may occur?
Basic Study Information
Purpose:
This trial will study SEA-BCMA to find out whether it is an effective treatment for
multiple myeloma (MM) and what side effects (unwanted effects) may occur.
The study will have three parts. In the first part, participants get SEA-BCMA by itself.
This part of the study will find out how much SEA-BCMA should be given for treatment
and how often. It will also find out how safe the treatment is and how well it works.
In the second part of the study, participants will get SEA-BCMA and dexamethasone.
In the third part, participants will get SEA-BCMA, dexamethasone, and either pomalidomide
or nirogacestat. Dexamethasone and pomalidomide are both drugs that can be used to
treat multiple myeloma. Nirogacestat is an experimental drug that can be used with
SEA-BCMA to treat multiple myeloma. These parts of the study will find out whether
these drugs are safe when used together.
Location: University of Rochester Medical Center
Study Reference #: IMMY18128
Lead Researcher (Principal Investigator)
Lead Researcher:
Brea Lipe
Study Contact Information
Study Contact: Clinical Trials Office
Study Location: Wilmot Cancer Institute, University of Rochester Medical Center
Study Email: WCICTOResearch@urmc.rochester.edu
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search